A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Erlotinib (Primary) ; Sirolimus (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2019.
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.